Abstract:Background Irisin, a newly identified peptide, is critical to regulating metabolism, thermogenesis, and reducing oxidative stresses. Our recent works demonstrated that irisin protected the heart against myocardial ischemic injury and preserved the function of mitochondria. However, whether irisin preserves myocardial performance and attenuates insulin resistance in type II diabetes remains unknown. Objective Effects of irisin on type II diabetes-induced cardiac dysfty unction and insulin resistance in db/db mice were studied. Methods: Homozygous db/db mice (n=5/each group) for spontaneous mutation (Lepr(db)) and heterozygous (heterozygous) mice (n=5/each group) for control were used to assess for cardiac performance and impairment of insulin resistance. Homozygous and heterozygous controls received a treatment with either irisin (100 mg/kg, intraperitoneal injection, every other day) or vehicle control (PBS) for 4 weeks at 16 weeks of age. Insulin tolerance test and glucose tolerance test were employed to determine insulin resistance in mice. Cardiac function was assessed by echocardiography. Metabolic features including hyperglycemia and body growth were also examined. Immunohistochemical analysis was employed to determine myocardial hypertrophy and interstitial fibrosis. Immunoblots were employed to determine the signaling pathway associated with irisin treatment. Results Homozygous db/db mice developed an impairment in insulin sensitivity as indicated by Insulin tolerance test (ITT), glucose tolerance test (GTT) (p<0.05 vs non-irisin treatment), hyperglycemia (p<0.05 vs heterozygous control), and hyperinsulinemia (serum insulin: 0.81 +/- 0.065 ng/ml in heterozygous control vs. 8.33 +/- 0.69 ng/ml in homozygous db/db control, p<0.0001), which were attenuated by the administration of irisin (serum insulin 8.32 +/- 0.68 ng/ml in homozygous db/db control vs 6.56 +/- 0.38 ng/ml in homozygous db/db irisin treatment, p<0.0001). Furthermore, as compared to heterozygous control, db/db mice manifested a depression in cardiac performance [ejection fraction (EF): 91.9% +/- 0.44 in heterozygous control vs 79.1% +/- 2.0 in homozygous db/db control, p< 0.001] in associated myocardial remodeling (cardiac fibrosis 1.89% +/- 0.09 in heterozygous control vs. 5.39% +/- 0.22 in homozygous db/db control, p<0.001). Notably, the depression of cardiac function in EF (79.2% +/- 2.0 homozygous db/db control vs. 88.6% +/- 1.9 in homozygous db/db + irisin, p<0.01) and fractional shortening (FS) (42.2% +/- 1.8 in homozygous db/db control vs. 53.2% +/- 2.7 in homozygous db/db+irisin, p<0.01) and remodeling were markedly attenuated by the administration of irisin. Western blotting shows that irisin treatment prevented an approximate two-fold decrease in p38 phosphorylation and increase in histone deacetylase 4 (HDAC4) in the homozygous db/db myocardium (p<0.05 vs homozygous db/db control). Conclusion Irisin preserves myocardial performance and insulin resistance in db/db mice, which is related to p38 phosphorylation and HDAC reduction.

Irisin alleviates FFA induced β-cell insulin resistance and inflammatory response through activating PI3K/AKT/FOXO1 signaling pathway

Irisin Reverses Insulin Resistance in C2C12 Cells Via the P38-Mapk-pgc-1α Pathway.

Irisin Improves Fatty Acid Oxidation and Glucose Utilization in Type 2 Diabetes by Regulating the AMPK Signaling Pathway.

Irisin alleviates the pyroptosis of β cells in T2DM by inhibiting NLRP3 inflammasome through regulating miR-19b-3p/SOCS3/STAT3 axis mediated autophagy

Irisin suppresses pancreatic β cell pyroptosis in T2DM by inhibiting the NLRP3-GSDMD pathway and activating the Nrf2-TrX/TXNIP signaling axis

Irisin Ameliorates Oxidative Stress-Induced Injury in Pancreatic Beta-Cells by Inhibiting Txnip and Inducing Stat3-Trx2 Pathway Activation.

Irisin Improves Endothelial Function in Type 2 Diabetes Through Reducing Oxidative/nitrative Stresses

Irisin Counteracts High Glucose and Fatty Acid-Induced Cytotoxicity by Preserving the AMPK-insulin Receptor Signaling Axis in C2C12 Myoblasts

Irisin Improves Insulin Resistance by Inhibiting Autophagy Through the PI3K/Akt Pathway in H9c2 Cells.

Exercise‐Induced Amelioration of Diet‐Induced Obesity and Diabetes is Not Regulated by Irisin

FNDC5 Overexpression and Irisin Ameliorate Glucose/lipid Metabolic Derangements and Enhance Lipolysis in Obesity

Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling

Irisin Deficiency Exacerbates Diet-Induced Insulin Resistance and Cardiac Dysfunction in Type II Diabetes in Mice

Irisin Prevents High-Fat Diet-Induced Metabolic Disorders Via Brown Adipose Tissue Activation

Irisin inhibits high glucose-induced endothelial-to-mesenchymal transition and exerts a dose-dependent bidirectional effect on diabetic cardiomyopathy.

Irisin Ameliorates Hypoxia/Reoxygenation-Induced Inflammation and Apoptosis in PC12 Cells by Inhibiting TLR4/MYD88 Signaling Pathway

[Irisin Alleviates Inflammatory Injury in Diabetic Cardiomyopathy by Regulating NF-κB Pathway]

Irisin Improves Myocardial Performance and Attenuates Insulin Resistance in Spontaneous Mutation (<i>Lepr<SUP>db</SUP></i>) Mice

Irisin Attenuates Myocardial Ischemia/Reperfusion Injury and Improves Mitochondrial Function Through AMPK Pathway in Diabetic Mice

Irisin ameliorates high glucose‐induced cardiomyocytes injury via AMPK/mTOR signal pathway

Exercise-Induced Irisin Decreases Inflammation and Improves NAFLD by Competitive Binding with MD2